Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04942548 · ClinicalTrials.gov registry record · NA
Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study
A NA study, sponsored by National Jewish Health.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT04942548: Completed NA study, sponsored by National Jewish Health.
NCT04942548 is a NA study that has completed, run by National Jewish Health. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04942548, a NA study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
This protocol is a prospective pilot study utilizing the intervention of a medically supervised, registered nurse and registered diabetes educator coached low-carbohydrate, ketogenic diet to examine the impact it has as a treatment for heart failure with preserved ejection fraction.
Primary Outcome
Change in score on the Minnesota Living with Heart Failure Quality of Life (MLHFQ) Questionnaire for the HFpEF cohort. * Max. Score = 105 * Min. Score = 0 * A reduced score means improvement of heart failure symptoms; better outcome
Interventions
- OTHER Ketogenic Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2023-07-24 |
| Phase | NA |
What the finished NCT04942548 record still lists
NCT04942548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Ketogenic Diet is the first listed.
NCT04942548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04942548 about?
NCT04942548 is a clinical study titled "Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study". This protocol is a prospective pilot study utilizing the intervention of a medically supervised, registered nurse and registered diabetes educator coached low-carbohydrate, ketogenic diet to examine the impact it has as a treatment for heart failure with preserved ejection fraction.
What is the current status of trial NCT04942548?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2019-07-25. Estimated completion is 2023-07-24.
What interventions are being tested in trial NCT04942548?
The interventions under investigation include: Ketogenic Diet (OTHER).
Who is sponsoring clinical trial NCT04942548?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04942548's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI